NCT06927375View on ClinicalTrials.gov

A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

November 12, 2025

Study Completion Date

March 12, 2026

Conditions
Thyroid-Associated Ophthalmopathy
Interventions
DRUG

Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg)

Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8. Flupentixol/Melitracen is given orally at a dose of 0.5 mg/10 mg twice daily for 8 consecutive weeks starting from Week 0.

DRUG

Tocilizumab(400mg)

Tocilizumab (Actemra) is administered via intravenous infusion at a dose of 400 mg at Weeks 0, 4, and 8.

Trial Locations (1)

200011

RECRUITING

Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors
lead

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

OTHER